Xponance Inc. Increases Position in Enovis Co. (NYSE:ENOV)

Xponance Inc. grew its holdings in shares of Enovis Co. (NYSE:ENOV) by 7.8% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 6,380 shares of the company’s stock after buying an additional 462 shares during the quarter. Xponance Inc.’s holdings in Enovis were worth $280,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Boston Partners increased its stake in Enovis by 27.1% in the fourth quarter. Boston Partners now owns 1,048,532 shares of the company’s stock worth $46,034,000 after purchasing an additional 223,816 shares during the period. Royce & Associates LP raised its position in Enovis by 2.8% during the 4th quarter. Royce & Associates LP now owns 2,470,576 shares of the company’s stock valued at $108,409,000 after purchasing an additional 66,891 shares in the last quarter. Envestnet Portfolio Solutions Inc. raised its holdings in shares of Enovis by 19.5% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 15,433 shares of the company’s stock valued at $677,000 after acquiring an additional 2,518 shares in the last quarter. Natixis Advisors LLC lifted its stake in Enovis by 52.8% in the fourth quarter. Natixis Advisors LLC now owns 19,381 shares of the company’s stock worth $850,000 after acquiring an additional 6,701 shares during the period. Finally, Ironwood Investment Management LLC grew its holdings in Enovis by 4.0% during the 4th quarter. Ironwood Investment Management LLC now owns 14,155 shares of the company’s stock worth $621,000 after acquiring an additional 545 shares in the last quarter. 98.45% of the stock is owned by institutional investors.

Enovis Stock Performance

ENOV stock opened at $38.89 on Friday. The firm has a 50-day simple moving average of $42.24 and a two-hundred day simple moving average of $43.38. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.12 and a current ratio of 2.27. Enovis Co. has a one year low of $35.14 and a one year high of $62.79. The firm has a market cap of $2.22 billion, a price-to-earnings ratio of -17.76 and a beta of 2.05.

Enovis (NYSE:ENOV) last issued its quarterly earnings results on Wednesday, February 26th. The company reported $0.98 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.92 by $0.06. The business had revenue of $560.98 million for the quarter, compared to the consensus estimate of $555.14 million. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. On average, equities analysts forecast that Enovis Co. will post 2.79 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC reduced their price target on shares of Enovis from $65.00 to $64.00 and set a “buy” rating for the company in a report on Thursday, February 27th.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.